Sermorelin: research reference

Distinguish local mechanism from integrated effect. A whole-axis result needs its time context and cannot be summarized by a receptor name.

The 1-29 fragment retains the minimal region described for binding to the GHRH receptor. Receptor activation increases cyclic AMP in cellular models.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

GHRH analog

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The oldest reference, from 1984, synthesized hpGRF(1–29) amide by solid phase alongside four derivatives: D-Tyr at position 1, D-Ala at 2, D-Asp at 3 and an N-terminally acetylated form. It measured subsequent growth-hormone secretion in rats and pigs as relative potency against the unchanged fragment. In rats, the D-Ala2 derivative was approximately fifty times as potent and the other three seven to twelve times as potent.

The 1999 review surveys this sequence as a stimulus of somatotropic function. Its material concerns pediatric populations and pituitary response rather than bench behavior.

Two further reviews place the compound within broader classes. The 2020 review lists it with growth-hormone secretagogues including GHRP-2, GHRP-6, ibutamoren and ipamorelin, noting limited published clinical data. The 2026 review orders GH–IGF-1-axis peptides by evidence level, from randomized trials to no human studies, and collects reported adverse-effect domains. Sources: PMID 6231028; PMID 18031173; PMID 32257855; PMID 42395176.

Two nonclinical references describe exposure. The 1988 work measured intravenous plasma half-life in rodents: 6.2 minutes for the unchanged fragment versus 4.7–7.4 minutes for D-amino-acid-substituted derivatives, a range the authors did not regard as different from the original.

The 1989 in vitro study identified a primary, single-step plasma cleavage by dipeptidyl peptidase between residues 2 and 3. Diprotin A, a competitive DPP-IV inhibitor, blocked it, while an aminopeptidase inhibitor did not; the process was not described as successive cleavages. A second tryptic-type cleavage occurred between residues 12 and 13 in fragment 1–29 but between 11 and 12 in the full hormone, a difference associated with truncated forms.

Neither reference describes albumin binding for sermorelin; the affinity complex belongs to a different class member. Lyophilized-material stability comes from declared handling and batch documentation, not these papers. Sources: PMID 2896343; PMID 2565342.

The molecule was obtained by truncation rather than de novo design. The 1980s literature called it human pancreatic growth hormone-releasing factor, or hpGRF. By 1984, amidated fragment 1–29 was the parent molecule against which derivative potency was measured in animals.

The choice of 29 rather than 44 residues is explained in the 1999 review: it describes the sequence as the shortest synthetic peptide retaining full GHRH biological activity, with subsequent residues unnecessary for that activity in that account.

Later analog design repeatedly targeted the same initial residues. In 1984, replacing position 1, 2 or 3 with a D-amino acid altered animal relative potency. In 1989, a D-residue at position 1 or 2 prevented dipeptidyl-peptidase cleavage in vitro. The amino terminus thus contains both potency-sensitive modifications and the primary cleavage site. Sources: PMID 6231028; PMID 18031173; PMID 2565342.

The 2026 review groups sermorelin with tesamorelin and both CJC-1295 variants, separating them from secretagogues such as ipamorelin, fragment 176–191 and IGF-1 LR3-type analogs. These are different classes, not a ranking.

Sermorelin is unchanged sequence 1–29. CJC-1295 No-DAC uses four substitutions, beginning with D-Ala at position 2—the change associated with preventing dipeptidyl-peptidase cleavage in vitro and the largest potency change in 1984. CJC-1295 DAC adds an albumin affinity complex to the fragment. Tesamorelin starts from the 44-residue hormone rather than fragment 1–29.

None of these references ranks the four by preference. The 2020 review describes sparse clinical data for its reviewed secretagogue group. Declared structure supports the comparison, not demonstrated relative performance. Sources: PMID 42395176; PMID 2565342; PMID 6231028; PMID 32257855.

Two references leave an unresolved tension. The 1989 in vitro study showed that a D-amino acid at position 1 or 2 prevents the main dipeptidyl-peptidase cleavage. A year earlier, D-substituted derivatives had rodent half-lives of 4.7–7.4 minutes versus 6.2 minutes for the unchanged fragment, without a difference called significant by the authors. Plasma enzymatic cleavage and intravenous half-life are different measurements, and no reference here reconciles them.

None measures sermorelin and the catalog’s other GHRH analogs in the same experiment. The 2026 review places some GH–IGF-1-axis peptides in a category with no human studies. These sources also lack albumin-binding and lyophilized-stability data. Sources: PMID 2565342; PMID 2896343; PMID 42395176.